Rifampicin treatment of cutaneous leishmaniasis.
In a small-scale preliminary trial of oral rifampicin treatment was considered successful in six out of eight cutaneous leishmaniasis patients and probably effective in a seventh. The in vitro effect of rifampicin on leishmania organisms concerns inhibition of mitochondrial function or replication. The need for protozoological control in the assessment of treatment is stressed.
D000293:Adolescent; D000328:Adult; D002648:Child; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy*; D008297:Male; D012293:Rifampin / Q000627:therapeutic use*
D012293:Rifampin